OTC : OPHLF

Ono Pharmaceutical Co., Ltd.

$14.45 USD

$0.05 (0.36%)

Volume
701
Average Volume
45
Market Capitalization
$6.79B
P/E Ratio
16.33
Dividend Yield
3.30%
Price Target
Year High
$18.67
Year Low
$10.27
Day High
—
Day Low
—
Payout Ratio
$0.54
Current Ratio
$2.86
Company Overview

OTC

Gyo Sagara

Drug Manufacturers - General

Healthcare

OPHLF

4206

JP

USD

https://www.ono-pharma.com

81 6 6263 5670

N/A

N/A

Liquidity Metrics

0.14

2.86

2.51

1.45

0.54

Sales & Valuation

$519.03B

2.21

1.34

8.71

277.70

Profitability

$148.6

$70.21B

13.53%

17.96%

8.54%

6.31%

P/E Metrics

16.33

0.42

0.42

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Poll Results

About Ono Pharmaceutical Co., Ltd. (OTC:OPHLF) Stock

Globally, Ono Pharmaceutical Co., Ltd., along with its affiliated entities, is engaged in the development, procurement, and commercialization of pharmaceutical products and diagnostic tools. Its product line features a wide array of therapeutic solutions, including several key oncology treatments such as OPDIVO, KYPROLIS, MEKTOVI, VELEXBRU, ADLUMIZ, and BRAFTOVI. It also offers EMEND and PROEMEND for managing chemotherapy-induced nausea and vomiting, and DEMSER for pheochromocytoma symptoms. For metabolic health, GLACTIV and FORXIGA target type 2 diabetes. The company provides medications for cardiovascular conditions (ONOACT for tachyarrhythmia, OPALMON for peripheral circulatory disorder, CORALAN for chronic heart failure) and autoimmune diseases (ORENCIA for rheumatoid arthritis). Neuro ... logical disorders are addressed with RIVASTACH for Alzheimer's and ONGENTYS for Parkinson's disease. Other significant offerings cover conditions such as overactive bladder (STAYBLA), bronchial asthma and allergic rhinitis (ONON), osteoporosis (RECALBON), and joint function improvement (JOYCLU), alongside PARSABIV for dialysis patients. Beyond its existing portfolio, the company maintains an active research and development pipeline, focusing on numerous therapeutic areas. This includes a broad spectrum of oncological conditions, such as various carcinomas (esophageal, urothelial, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, non-small cell lung), lymphomas (Hodgkin's, primary central nervous system), melanoma, acute myeloid leukemia, myelodysplastic syndrome, and virus-positive/negative solid tumors. Its developmental efforts also extend to inflammatory and autoimmune disorders like polymyositis/dermatomyositis, pemphigus, generalized scleroderma, and enthesopathy, as well as cardiovascular issues (tachyarrhythmia, thrombosis), neurodegenerative diseases, diabetic polyneuropathy, and conditions such as narcolepsy. Established in 1717, this long-standing enterprise operates from its main office in Osaka, Japan.

Should Value Investors Buy Ono Pharmaceutical Co. (OPHLF) Stock?

2026-07-13 10:40:30

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?

2026-07-07 07:11:05

Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting

2026-06-01 19:00:00

OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced the results of the phase 2 clinical study (ONO-4578-08 study) of the EP4 antagonist ONO-4578 in patients with previously untreated, HER2-negative unresectable advanced or recurrent gastric cancer (including gastroesophageal junction cancer).

Frequently Asked Questions

What is the current Ono Pharmaceutical Co., Ltd. (OPHLF) stock price?

Ono Pharmaceutical Co., Ltd.(OTC:OPHLF) stock price is $14.45 in the last trading session. During the trading session, OPHLF stock reached the peak price of $18.67 while $10.27 was the lowest point it dropped to. The percentage change in OPHLF stock occurred in the recent session was 0.36% while the dollar amount for the price change in OPHLF stock was $0.05.

OPHLF's industry and sector of operation?

The OTC listed OPHLF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of OPHLF?

Masaki Ito | Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div.
Satoshi Takahagi | Senior Director of EHS Promotion & Corporate Officer
Akira Takada | Corporate Executive Officer & Executive Director of CMC & Production
Hiromu Habashita | Corporate Officer, Senior Vice President, Discovery & Research
Hiroyuki Takahashi | Director of Oncology Business Division

How many employees does OPHLF have?

Number of OPHLF employees currently stands at 4206. OPHLF operates from 8-2, Kyutaromachi 1-chome, Osaka, OS 541-8564, JP.

Link for OPHLF official website?

Official Website of OPHLF is: https://www.ono-pharma.com

How do I contact OPHLF?

OPHLF could be contacted at phone #81 6 6263 5670 and can also be accessed through its website. OPHLF operates from 8-2, Kyutaromachi 1-chome, Osaka, OS 541-8564, JP.

How many shares of OPHLF are traded daily?

The average number of OPHLF shares traded daily for last 3 months was 45.

What is the market cap of OPHLF currently?

The market value of OPHLF currently stands at $6.79B with its latest stock price at $14.45